EU-India trade deal could derail generic supply chain, MSF warns
This article was originally published in Scrip
Médecins Sans Frontières (MSF) has warned that the stringent intellectual property enforcement and injunction measures in the proposed EU-India free trade agreement (FTA) could have "chilling" implications for the entire generic medicine supply chain. The international NGO says that the free trade agreement as drafted imposes another piece of legislation, the Anti-Counterfeiting Trade Agreement (ACTA), implementation of which would threaten a range of programmes including those funded by the US President's Emergency Plan for AIDS Relief, UNITAID and the Global Fund, and hurting active pharmaceutical ingredients suppliers from India and possibly China.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?